Andreas Reichel
Company: Bayer
Job title: Vice President, Head of DMPK M&S
Seminars:
2:00 PROTAC Discovery – Why is PK/PD Modelling Essential? 9:30 am
How can PK/PD modelling inform experimental study design and data evaluation both in vitro and in vivo ? What are the parameters that make an efficient degrader ? How can we link target degradation in vitro to pharmacodynamic effects and how can we translate this to the in vivo situation ?Read more
day: Day 1 Track B morning
2:30 Roundtable Discussion: Discussing Unique PK/PD Properties of Degraders 10:15 am
Given the notoriously low oral bioavailability of PROTACs, what is your strategy to achieve efficacious concentrations in vivo? What is your view regarding PK/PD requirements for long-acting parenteral PROTACs? Have you observed any loss of efficacy after repeat treatment and, if so, what could be the potential mechanisms?Read more
day: Day 1 Track B morning
Chair’s Opening Remarks 8:50 am
day: Day One